Who mentions $BIIB most on Surfaced?

@adamfeuerstein (Adam Feuerstein ✡️) mentions $BIIB most — 6 mentions in the past 12 months.

When was $BIIB first mentioned on Surfaced?

The earliest tracked mention of $BIIB in the Surfaced archive was on Dec 15, 2025.

How many voices track $BIIB?

5 FinTwit voices have mentioned $BIIB 10 times in the past 12 months.

What kind of voices mention $BIIB most?

$BIIB is mentioned most by Biotech voices on Surfaced.

Last 12mo stats

mentions

voices

$BIIB

Biogen Inc

$BIIB

Biogen Inc

Past 12mo:10mentions5voices

All voices10 mentions since Dec 2025calls only

Loading price chart…

About this stock

$BIIB received 10 mentions from 5 distinct FinTwit voices over a 12-month period, with the first mention appearing on December 15, 2025, and the most recent on July 16, 2026. @adamfeuerstein dominated discussion with 6 mentions, while @investmentguru_, @jacobplieth, @ssi_invest, and @yasutaketin each contributed 1 mention. The biotech category accounted for the most active voice contributions regarding this ticker.

Recent discussion centered on $BIIB's tau-targeting drug for Alzheimer's disease. On July 14, 2026, @adamfeuerstein reported that "Diranersen slowed cognitive decline as 26% compared to a placebo, in line with efficacy shown by currently approved amyloid drugs" following results revealed at #AAIC26. Prior coverage on July 12 previewed the tau drug study presentation, while July 16 commentary noted thoughts on the company's tau drug within a broader biotech newsletter covering multiple therapeutic areas.

AI-generated from tracked posts · updated Jul 17, 2026

Related stocks

$ARWRArrowhead Pharmaceuticals

$ATYRAtyr Pharma

$SNDXSyndax Pharmaceuticals

$TERNTerns Pharmaceuticals

Recent mentions

10 mentions

@adamfeuersteinJul 16, 2026 · 2:28 PM

This week's Biotech Scorecard newsletter: I chatted with $AMLX co-CEOs Johua Cohen and Justin Klee about avexitide, their GLP-1 ANTAGONIST nearing read out of a pivotal study in a rare endocrine disorder. Also, a thought or two on $BIIB and its tau drug for Alzheimer's; and the FDA review of $AGIO 's treatment for sickle cell disease. https://t.co/lhM4lBmQkH

Open on X

@adamfeuersteinJul 14, 2026 · 1:17 PM

$BIIB tau drug results just revealed at #AAIC26 Diranersen slowed cognitive decline as 26% compared to a placebo, in line with efficacy shown by currently approved amyloid drugs. https://t.co/8AiMigjW1K via @DrewQJoseph

Open on X

@adamfeuersteinJul 12, 2026 · 8:49 PM

My London colleague @DrewQJoseph is attending #AAIC26. Here's his first report: A preview of $BIIB 's tau-targeting drug study that will be presented on Tuesday. Plus: 🧠Alzheimer’s Association CEO on fraught scientific times 🧠progress getting drugs across the blood-brain barrier $DNLI 🧠FDA on ARIA https://t.co/XnJbFj4zUp

Open on X

@adamfeuersteinMay 14, 2026 · 11:11 AM

$BIIB Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study Diranersen (BIIB080) reduced tau and slowed cognitive decline but Biogen is not disclosing details until the AAIC meeting in July. The study also failed to show a dose response, which was the primary endpoint. https://t.co/Y05ynUZWTx

Open on X

@ssi_investApr 3, 2026 · 8:31 AM

Biogen is making a major move in rare disease. - $APLS to be acquired by $BIIB - $41.00/sh cash + $4.00 CVR - Tiny spread to cash + "free option" CVR - ~14% shareholder support already locked - Syfovre sales milestones drive CVR payouts - CVR milestones unlikely to be hit https://t.co/6htzCtB4Xu

Open on X

@adamfeuersteinMar 31, 2026 · 12:01 PM

Biogen $BIIB to acquire immunology biotech Apellis $APLS for $5.6 billion https://t.co/07hf3RyfZG via @elaineywchen

Open on X

@adamfeuersteinMar 31, 2026 · 11:02 AM

$BIIB buying $APLS $5.6B https://t.co/qeuVoHloo7

Open on X

@investmentguru_Mar 27, 2026 · 11:59 AM

$QNTM – From Speculative Microcap to Multi-Catalyst Biotech Story Unfolding Over the past week, $QNTM has quietly delivered a series of developments that signal a clear transition from hype to execution — and the market hasn’t fully priced it in yet. First, the financial foundation has improved significantly. The company now holds approximately $11.3M in cash and digital assets, with a projected runway extending into 2028. On top of that, management has reduced payables by nearly 50% and lowered operating expenses year-over-year. In a sector where most microcap biotechs struggle with survival and constant dilution, this matters. A stronger balance sheet gives $QNTM the ability to focus on execution rather than emergency financing. Now to the core asset — Lucid-MS. Lucid-MS is being developed to target demyelination in multiple sclerosis, addressing the root cause rather than just managing symptoms. It’s also an oral therapy, which gives it a major advantage over current treatments that rely on injections or infusions. Recent progress has been meaningful: •Phase 1 trials and toxicity studies completed with no major safety concerns •IND filing for Phase 2 expected in H1 2026 •Dr. Salvatore Napoli appointed as Principal Investigator for Phase 2 That last point is critical — you don’t bring in trial leadership unless you are preparing to execute. This signals that $QNTM is entering a key value inflection stage. In parallel, the company is working with researchers at Massachusetts General Hospital, where early-stage patient imaging is already underway. This adds a layer of scientific validation that many microcaps lack. But what makes $QNTM unique is that it’s not a one-dimensional biotech. The company also has a near-term monetization angle through its consumer product, Unbuzzd. Unbuzzd just achieved a major milestone: its clinical trial was published in a peer-reviewed journal, confirming that it can: •Accelerate alcohol metabolism •Reduce intoxication effects •Improve mental clarity This is a rare combination — a product with both clinical backing and consumer appeal. Even more interesting: •$QNTM owns roughly 20% of the Unbuzzd business •It receives royalty revenue (7% up to $250M) •There is potential for an IPO, which could unlock non-dilutive capital On top of that, Health Canada has already approved Qlarity, opening a commercial pathway in Canada. And recently, the company closed a $3.75M financing tranche, further strengthening its ability to execute upcoming milestones. When you step back, the full picture becomes clear: $QNTM now has: •A progressing MS drug entering Phase 2 •A clinically validated consumer product with monetization potential •Improved financial stability with extended runway •Multiple near-term catalysts •Optional upside from a legal case against major financial institutions Yet, it is still being priced like a high-risk, early-stage microcap. That disconnect is where opportunity lives. This is exactly the type of setup where asymmetric upside is created. The market often ignores these names during accumulation phases… and then reprices them aggressively when catalysts start hitting. Paid #advertisement got paid for this promotion Disclaimer: https://t.co/zhpDBya1ZL DYOR, not a financial advice. Other biotech- $BIIB $DNLI $ALKS $ACIU

Open on X

@jacobpliethMar 6, 2026 · 2:50 PM

$DAWN acquisition by Servier for $2.5bn is quite the ending for Ojemda. Who remembers this RAF inhibitor's bizarre & convoluted history? $BIIB $TAK https://t.co/uD5drO9ymr

Open on X

@yasutaketinDec 15, 2025 · 2:23 AM

ビットコイン買いだめ企業のストラテジー、ナスダック100に残る $MSTR ・除外銘柄 $BIIB (バイオジェン) $CDW (CDW) $GFS (グローバルファウンドリーズ) $LULU (ルルレモン・アスレティカ) $ON (オン・セミコンダクター) $TTD (トレードデスク) ・新規採用銘柄 $ALNY (アルナイラム・ファーマシューティカルズ) $FER (フェロヴィアル) $INSM (インスメド) $MPWR (モノリシック・パワー・システムズ) $STX (シーゲイト・テクノロジー) $WDC (ウエスタンデジタル) ・ナスダックの銘柄変更は12月22日に実施される予定 https://t.co/CKwIUsGPyl

Open on X

About this stock

Related stocks

Frequently asked